REHOVOT, Israel and NEW YORK, Feb. 01, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics INC (OTC:KKIC), a leading anti-microbial therapeutic company, today announced the appointment of Hai Aviv as the Company’s Chief Financial Officer, effective February 28, 2017.
“We are excited to have Hai join the AIT team,” said Amir Avniel, Chief Executive Officer of AIT Therapeutics INC. “Hai brings a wealth of financial and operational experience to AIT, which should become a major asset as we build infrastructure for the Company and execute on late stage clinical trials for our RSV and NTM product candidates.”
Mr. Aviv, 35 years old, will join the Company from Babylon Ltd., a publicly-traded Israeli company listed on the Tel Aviv Stock Exchange and operating in the fields of internet, risk capital investments and software, where he was most recently the Chief Financial Officer. In his role he was actively involved in the company’s IPO on NASDAQ, and also worked on mergers, acquisitions, and investments. From 2010 to 2013, Mr. Aviv was Babylon’s Corporate Controller. From 2005 to 2010, he was a manager at the Ernst & Young Accounting Firm of Kost Forer, Gabbay & Kasierer, in Tel Aviv, working predominantly with the high-tech team. Mr. Aviv is a Certified Public Accountant, and holds a Bachelor of Arts degree in Business and Accounting, and an MBT in Business and Taxation from The College of Management, Israel.
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a biopharmaceutical company developing novel anti-microbial therapeutics for respiratory diseases based on Nitric Oxide. The Company is applying its therapeutic expertise to address significant medical needs, many of which cannot effectively be addressed with current standards of care, including small molecules and antibodies. AIT Therapeutics Inc. is building a pipeline for the treatment of respiratory syncytial virus (RSV) infection and Non Tuberculosis Mycobacterium (NTM).The Company’s leadership position in fundamental patents, technology, and know-how relating to NO has enabled it to develop a unique Nitric Oxide drug formulation for the treatment of RSV infection and NTM For more information, visit www.AIT-Pharm.com.
Various statements in this release concerning our future expectations, plans, and prospects, including without limitation, statements concerning the use of Nitric Oxide therapeutics for the treatment of RSV or NTM and other diseases and the availability of results of clinical trials and studies, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history; In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.
Source: AIT Therapeutics, Inc.